SCHEMBL925099

SCHEMBL925099

CCCCCCCC(=O)Oc1c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c2c1=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLH Q9Y253 8/20 0.71
SRC P12931 4/20 0.64
TOP2A P11388 1/20 0.64
KDM4E B2RXH2 2/20 0.64
MEN1 O00255 2/20 0.64
MMP1 P03956 2/20 0.64
POLB P06746 2/20 0.64
GAA P10253 2/20 0.64
MAPT P10636 2/20 0.64
APEX1 P27695 2/20 0.64
RECQL P46063 2/20 0.64
BLM P54132 2/20 0.64
KMT2A Q03164 2/20 0.64
HSD17B10 Q99714 2/20 0.64
HTT P42858 1/20 0.64
EPHX2 P34913 2/20 0.62
ALOX5 P09917 3/20 0.55
BCL9 O00512 1/20 0.55
ABCC4 O15439 1/20 0.55
MGAM O43451 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4163382 1.00 POLH (0.71) POLHSRCTOP2AKDM4EMEN1
SCHEMBL4153380 1.00 POLH (0.71) POLHSRCTOP2AKDM4EMEN1
SCHEMBL31236656 1.00 POLH (0.71) POLHSRCTOP2AKDM4EMEN1
SCHEMBL4175309 1.00 POLH (0.71) POLHSRCTOP2AKDM4EMEN1
SCHEMBL4170099 1.00 POLH (0.71) POLHSRCTOP2AKDM4EMEN1
SCHEMBL4159135 1.00 POLH (0.71) POLHSRCTOP2AKDM4EMEN1
SCHEMBL4170035 1.00 POLH (0.71) POLHSRCTOP2AKDM4EMEN1
SCHEMBL4172289 1.00 POLH (0.71) POLHSRCTOP2AKDM4EMEN1
SCHEMBL4170652 1.00 POLH (0.71) POLHSRCTOP2AKDM4EMEN1
SCHEMBL4169970 0.99 POLH (0.73) POLHSRCTOP2AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4326892-A1 METHOD FOR SELECTING ECOBIOLOGICAL TOPICAL COMPOSITIONS AND INGREDIENTS CAPABLE OF RESTORING OR REINFORCING THE SKIN MICROBIOTA NAOS Institute of Life Science (FR) 2024-02-28 EP claimed
WO-2022223928-A1 METHOD FOR SELECTING ECOBIOLOGICAL TOPICAL COMPOSITIONS AND INGREDIENTS CAPABLE OF RESTORING OR REINFORCING THE SKIN MICROBIOTA NAOS INSTITUTE OF LIFE SCIENCE (FR) 2022-10-27 WO claimed
US-20210244635-A1 ENZYMATIC MOLECULE MIMICKING ANTI-OXIDANT ACTIVITY BIONUCLEI (FR) 2021-08-12 US claimed
EP-3801058-A1 ENZYMATIC MOLECULE MIMICKING ANTI-OXIDANT ACTIVITY Bionuclei (FR) 2021-04-14 EP claimed
CN-112533493-A Enzyme molecules that mimic antioxidant activity 比奥尼克莱公司 2021-03-19 CN claimed
US-8980344-B2 Skin care products containing multiple enhancers SHISEIDO AMERICAS CORPORATION 2015-03-17 US claimed
US-20120171156-A1 METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES HDS LTD. (GB) 2012-07-05 US claimed
EP-2442873-A2 METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES Hds Limited (GB) 2012-04-25 EP claimed
WO-2010146142-A9 METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES HDS LIMITED (GB) 2011-06-16 WO claimed
US-20110034427-A1 Anti-aging properties of quercetin, 18alpha-glycyrrhetinic acid and hederagenin and their derivatives KORRES S.A. NATURAL PRODUCTS (GR) 2011-02-10 US claimed
WO-2010146142-A2 METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES HDS LIMITED (GB) 2010-12-23 WO claimed
EP-2246037-A2 Anti-aging and whitening properties of quercetin, 18a-glycyrrhetinic acid, hederagenin and its derivatives Korres S.A. Natural Products (GR) 2010-11-03 EP claimed
US-20090130051-A1 Flavonoid Compounds and Uses Thereof HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) 2009-05-21 US claimed
US-20090117061-A1 SKIN CARE PRODUCTS CONTAINING MULTIPLE ENHANCERS SHISEIDO AMERICAS CORPORATION 2009-05-07 US claimed
WO-2009046116-A1 SKIN CARE PRODUCTS CONTAINING MULTIPLE ENHANCERS GROSS DENNIS (US) 2009-04-09 WO claimed
US-20240390406-A1 PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) 2024-11-28 US disclosed
EP-4467978-A1 PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS King Faisal Specialist Hospital & Research Centre (SA) 2024-11-27 EP disclosed
WO-2008080892-A1 UV ABSORBER FORMULATIONS CIBA HOLDING INC. (CH) 2008-07-10 WO disclosed
WO-2008070368-A2 METHODS AND COMPOSITIONS FOR SKIN CARE LIVING PROOF, INC. (US) 2008-06-12 WO disclosed
WO-2007137958-A2 SELF TANNING COMPOSITION CIBA HOLDING INC. (CH) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034427-A1 Anti-aging properties of quercetin, 18alpha-glycyrrhetinic acid and hederagenin and their derivatives GLA, AGER, CUTA POLH 191/4885SRC 4852/4885TOP2A 942/4885
US-20090130051-A1 Flavonoid Compounds and Uses Thereof CAT, NQO1, GPX4 POLH 3392/4885SRC 2708/4885TOP2A 4491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.